Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
Status:
Completed
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, fixed-sequence study in healthy Chinese subjects, performed at
a single study centre. Cohort A will assess the Pharmacokinetic (PK) profile of rongliflozin
when administered alone and the combination with rifampicin; Cohort B will assess the PK
profile of rongliflozin when administered alone and combination with probenecid.